Awaiting development: Guidance and quality standards

Showing 341 to 350 of 359

Guidance and quality standards awaiting development
Title	Type
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance
Vonaprument for treating geographic atrophy caused by age-related macular degeneration	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]	Technology appraisal guidance